Hamilton Capital Partners (Canada)’s Regeneron Pharmaceuticals REGN Stock Holding History

Hamilton Capital Partners (Canada)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,605	Closed	-$2.57M	–	211
2024 Q4	$2.57M	Sell	3,605 -403	-10%	-$338K	0.19%	95
2024 Q3	$4.21M	Sell	4,008 -931	-19%	-$1.04M	0.36%	74
2024 Q2	$5.19M	Buy	4,939 +270	+6%	+$262K	0.56%	54
2024 Q1	$4.49M	Buy	+4,669	New	+$4.44M	0.54%	64

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hamilton Capital Partners (Canada)'s REGN Position: Q1 2025 in Review

Hamilton Capital Partners (Canada) sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 3,605 shares — an estimated $2.57M sold.

Hamilton Capital Partners (Canada) first reported a position in REGN in Q1 2024 and held it in 4 quarters. The position peaked at $5.19M in Q2 2024. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Hamilton Capital Partners (Canada) reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Hamilton Capital Partners (Canada) sold 3,605 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $2.57M.
Hamilton Capital Partners (Canada) first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Hamilton Capital Partners (Canada)'s Regeneron Pharmaceuticals position peaked at $5.19M in Q2 2024.
1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Hamilton Capital Partners (Canada)'s 13F filing for Q1 2025, filed 14 Aug 2026.